Azithromycin + Telithromycin
ApprovedTerminated 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Maxillary Sinusitis
Conditions
Maxillary Sinusitis
Trial Timeline
Dec 1, 2005 → Jul 1, 2006
NCT ID
NCT00245440About Azithromycin + Telithromycin
Azithromycin + Telithromycin is a approved stage product being developed by Sanofi for Maxillary Sinusitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00245440. Target conditions include Maxillary Sinusitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00245440 | Approved | Terminated |
Competing Products
5 competing products in Maxillary Sinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin | Johnson & Johnson | Phase 3 | 77 |
| Azithromycin SR + Amoxiclav 1000 mg | Pfizer | Pre-clinical | 22 |
| azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin | Pfizer | Phase 3 | 76 |
| Telithromycin | Sanofi | Phase 3 | 76 |
| Avelox (Moxifloxacin, BAY12-8039) | Bayer | Approved | 82 |